Why it hits harder
Tirzepatide is a once-weekly peptide that does something the earlier weight-loss drugs didn't: it activates two gut-hormone receptors at once — GIP and GLP-1. Older drugs like semaglutide hit just one.
That dual action is the leading explanation for why, head to head, tirzepatide has produced the biggest weight reductions seen in the drug class.
The landmark trial
SURMOUNT-1, published in the New England Journal of Medicine in 2022, was a rigorous Phase 3 trial: 2,539 adults with obesity, 72 weeks, randomized against placebo.
Average weight loss was 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg — versus just 3.1% on placebo. At the top dose, 91% of people lost at least 5% of their body weight, and 57% lost 20% or more. The most common side effects were gastrointestinal — mostly mild to moderate, and concentrated during the dose ramp-up.
The part people skip
A follow-up trial, SURMOUNT-4 (JAMA, 2024), tested what happens when you stop. After everyone lost weight, half were switched to placebo — and regained about 14%, while those who kept going lost a further 5.5%.
The honest translation: this is a treatment you stay on, not a course you finish. The biology that drives the weight off is the same biology that lets it come back.
Unmatched weight-loss numbers in well-run trials — with two asterisks the research is clear about: the benefit depends on staying on it, and GI side effects are common while ramping the dose.